1. Home
  2. ESNT vs MIST Comparison

ESNT vs MIST Comparison

Compare ESNT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESNT
  • MIST
  • Stock Information
  • Founded
  • ESNT 2008
  • MIST 2003
  • Country
  • ESNT Bermuda
  • MIST Canada
  • Employees
  • ESNT N/A
  • MIST N/A
  • Industry
  • ESNT Property-Casualty Insurers
  • MIST Biotechnology: Pharmaceutical Preparations
  • Sector
  • ESNT Finance
  • MIST Health Care
  • Exchange
  • ESNT Nasdaq
  • MIST Nasdaq
  • Market Cap
  • ESNT N/A
  • MIST 145.3M
  • IPO Year
  • ESNT 2013
  • MIST N/A
  • Fundamental
  • Price
  • ESNT $63.55
  • MIST $1.94
  • Analyst Decision
  • ESNT Buy
  • MIST Strong Buy
  • Analyst Count
  • ESNT 6
  • MIST 3
  • Target Price
  • ESNT $63.67
  • MIST $6.33
  • AVG Volume (30 Days)
  • ESNT 467.6K
  • MIST 1.2M
  • Earning Date
  • ESNT 10-31-2025
  • MIST 11-11-2025
  • Dividend Yield
  • ESNT 1.94%
  • MIST N/A
  • EPS Growth
  • ESNT N/A
  • MIST N/A
  • EPS
  • ESNT 6.85
  • MIST N/A
  • Revenue
  • ESNT $1,268,306,000.00
  • MIST N/A
  • Revenue This Year
  • ESNT $4.27
  • MIST N/A
  • Revenue Next Year
  • ESNT $1.47
  • MIST N/A
  • P/E Ratio
  • ESNT $9.32
  • MIST N/A
  • Revenue Growth
  • ESNT 5.28
  • MIST N/A
  • 52 Week Low
  • ESNT $51.61
  • MIST $0.63
  • 52 Week High
  • ESNT $65.34
  • MIST $2.75
  • Technical
  • Relative Strength Index (RSI)
  • ESNT 57.34
  • MIST 64.09
  • Support Level
  • ESNT $62.44
  • MIST $1.75
  • Resistance Level
  • ESNT $64.42
  • MIST $2.06
  • Average True Range (ATR)
  • ESNT 0.96
  • MIST 0.09
  • MACD
  • ESNT -0.21
  • MIST 0.02
  • Stochastic Oscillator
  • ESNT 64.05
  • MIST 66.67

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: